Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Tolcapone and entacapone are catechol-O-methyltransferase (COMT) inhibitors developed as adjunct therapies for treating Parkinson's disease. While both drugs have been shown to cause mitochondrial dysfunction and inhibition of the bile salt export protein (BSEP), liver injury has only been associated with the use of tolcapone. Here we used a multiscale, mechanistic model (DILIsym(®)) to simulate the response to tolcapone and entacapone. In a simulated population (SimPops™) receiving recommended doses of tolcapone (200 mg t.i.d.), increases in serum alanine transaminase (ALT) >3× the upper limit of normal (ULN) were observed in 2.2% of the population. In contrast, no simulated patients receiving recommended doses of entacapone (200 mg 8× day) experienced serum ALT >3× ULN. Further, DILIsym(®) analyses revealed patient-specific risk factors that may contribute to tolcapone-mediated hepatotoxicity. In summary, the simulations demonstrated that differences in mitochondrial uncoupling potency and hepatic exposure primarily account for the difference in hepatotoxic potential for tolcapone and entacapone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis.
Pérez-Carreras, M., Del Hoyo, P., Martín, M. A., Rubio, J. C., Martín, A., Castellano, G., Colina, F., Arenas, J., & Solis-Herruzo, J. A. (2003) · Hepatology · doi:10.1002/hep.1840380426 · Cited by 734
Fattinger, K. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114667 · Cited by 509
Morgan, R. E., van Staden, C. J., Chen, Y., Kalyanaraman, N., Kalanzi, J., Dunn, R. T., Afshari, C. A., & Hamadeh, H. K. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft176 · Cited by 243 · cited 5×
“In addition, recent work using in vitro systems has demonstrated that both drugs have the potential to alter hepatobiliary transport.(10) Tolcapone and entacapone caused modest inhibition of the bile salt export pump (BSEP), an efflux transporter that secretes bile acids (BAs) from the liver into the bile, and the bas…”
BackgroundInfluentialMitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Shoda, L. K. M., Woodhead, J. L., Siler, S. Q., Watkins, P. B., & Howell, B. A. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1878 · Cited by 75
Self-citation
Cited by
Drug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
Segovia-Zafra, A., Di Zeo-Sánchez, D. E., López-Gómez, C., Pérez-Valdés, Z., García-Fuentes, E., Andrade, R. J., Lucena, M. I., & Villanueva-Paz, M. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.013 · Cited by 70
Shankaran, H., Cronin, A., Barnes, J., Sharma, P., Tolsma, J., Jasper, P., & Mettetal, J. T. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12255 · Cited by 20
Pfeifer, L. M., Sensbach, J., Pipp, F., Werkmann, D., & Hewitt, P. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1439031 · Cited by 13
Metadata
- Authors
- Longo, D., Yang, Y., Watkins, P., Howell, B., & Siler, S.
- Venue
- CPT: Pharmacometrics & Systems Pharmacology
- Publisher
- Wiley
- Published
- 2016-01
- Volume
- 5
- Issue
- 1
- Pages
- 31-39
- ISSN
- 2163-8306 (ISSN-L)
- OpenAlex
- W2238806746
- Cited by
- 73
- References
- 6
- FWCI
- 13.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury. https://app.cochat.ai/papers/10.1002/psp4.12053
- The paper
- Longo, D., Yang, Y., Watkins, P., Howell, B., & Siler, S. (2016). Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.12053
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.